Wellington Management Group LLP Has $86.34 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Wellington Management Group LLP boosted its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,033,743 shares of the biopharmaceutical company’s stock after purchasing an additional 16,096 shares during the quarter. Wellington Management Group LLP’s holdings in Intra-Cellular Therapies were worth $86,338,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new stake in Intra-Cellular Therapies in the 4th quarter valued at $268,347,000. Raymond James Financial Inc. bought a new stake in Intra-Cellular Therapies in the fourth quarter valued at about $76,451,000. TimesSquare Capital Management LLC lifted its stake in Intra-Cellular Therapies by 91.8% during the fourth quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock worth $70,179,000 after purchasing an additional 402,186 shares during the period. Franklin Resources Inc. boosted its holdings in Intra-Cellular Therapies by 9.7% during the third quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock valued at $129,463,000 after purchasing an additional 155,655 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Intra-Cellular Therapies by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock valued at $811,928,000 after purchasing an additional 93,107 shares during the period. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on ITCI shares. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $140.00 to $132.00 in a report on Monday, February 24th. Piper Sandler restated a “neutral” rating and issued a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Royal Bank of Canada reissued a “sector perform” rating and set a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Eleven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $106.23.

Intra-Cellular Therapies Stock Performance

Shares of Intra-Cellular Therapies stock opened at $131.87 on Friday. Intra-Cellular Therapies, Inc. has a 52 week low of $64.09 and a 52 week high of $131.98. The stock has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. The firm has a fifty day moving average of $129.62 and a two-hundred day moving average of $101.43.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. As a group, research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.